What infection screening tests and vaccinations should be completed before initiating rituximab therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Pre-Rituximab Evaluation and Vaccination Protocol

All patients must undergo hepatitis B screening (HBsAg, anti-HBcore, anti-HBs) before initiating rituximab, and complete all indicated vaccinations at least 2 weeks prior to the first dose. 1

Mandatory Infection Screening

Hepatitis B Virus (HBV) - Critical Priority

Screen every patient with:

  • HBsAg (hepatitis B surface antigen)
  • Anti-HBcore (hepatitis B core antibody)
  • Anti-HBs (hepatitis B surface antibody)

Management based on results: 2

  • HBsAg-positive (active carriers): Refer to hepatology for antiviral prophylaxis before starting rituximab
  • Anti-HBcore-positive, HBsAg-negative (resolved infection):
    • Check HBV-DNA at baseline
    • For rituximab specifically: Consider prophylactic antivirals regardless of DNA levels due to high reactivation risk with anti-CD20 therapy
    • If not on prophylaxis, monitor HBV-DNA and liver function tests every 3-6 months
  • All markers negative: No prior exposure, proceed with treatment

The evidence strongly supports this screening - rituximab carries particularly high risk for HBV reactivation compared to other immunosuppressants, with reactivation rates of 30% in high-risk groups and potential for fatal liver decompensation. 2, 3, 4, 5 Despite this, real-world data shows only 10-60% of patients are appropriately screened, representing a critical gap in care. 6, 4

Hepatitis C Virus (HCV)

Screen with anti-HCV antibodies if:

  • Elevated ALT/liver enzymes
  • Known risk factors (IV drug use, blood transfusions pre-1992)

If anti-HCV positive, check HCV-RNA and refer for antiviral treatment consideration. 2

HIV Screening

Recommended prior to rituximab initiation, particularly in patients with risk factors or from higher prevalence populations. 2

Tuberculosis (TB)

Screen all patients before rituximab with:

  • Tuberculin skin test (TST) or Interferon-gamma release assay (IGRA)

If positive, treat latent TB per national guidelines (typically isoniazid 6-12 months or rifampin-based regimens) before starting rituximab. Monitor liver function if combining TB treatment with hepatotoxic medications. 2, 3

Baseline Laboratory Monitoring

  • Complete blood count (CBC) with differential and platelets before first dose 1
  • Continue CBC monitoring every 2-4 months during therapy for autoimmune conditions

Vaccination Strategy - Timing is Critical

The single most important principle: Vaccinate BEFORE starting rituximab whenever possible. Rituximab profoundly impairs vaccine responses for 6-12 months after administration. 7, 8

Pre-Treatment Vaccination Protocol

Administer all indicated vaccines at least 2 weeks before the first rituximab dose to allow adequate immune response development. 7

Priority vaccines to complete:

  • Influenza (annual, inactivated)
  • Pneumococcal vaccines:
    • PCV13 or PCV15 (conjugate vaccine) first
    • PPSV23 (polysaccharide) 8 weeks later
  • COVID-19 (complete primary series plus boosters)
  • Hepatitis B vaccine if non-immune (all three markers negative)
  • Herpes zoster (Shingrix preferred - recombinant, non-live)
  • Tdap if not up to date

Avoid all live vaccines - these are contraindicated with rituximab. This includes MMR, varicella, live zoster (Zostavax), and live intranasal influenza.

If Already on Rituximab - Salvage Vaccination Strategy

For patients already receiving rituximab who need vaccination: 7

Influenza vaccine: Give on schedule regardless of rituximab timing (don't wait), then delay next rituximab dose by at least 2 weeks if disease activity permits

All other non-live vaccines:

  • Optimal timing: Administer when next rituximab dose is due (maximum B-cell recovery)
  • Then delay rituximab for at least 2 weeks after vaccination
  • This improves immunogenicity compared to vaccinating shortly after rituximab

Recent evidence shows that patients vaccinated before rituximab initiation achieve 87-91% seroconversion rates, comparable to healthy controls, versus only 61-65% in those vaccinated while on rituximab. 8 Antibody responses can recover if vaccines are given ≥9 months after the last rituximab dose.

Common Pitfalls to Avoid

  1. Starting rituximab without HBV screening - This remains the most dangerous oversight, with potentially fatal consequences from reactivation 6, 4, 5

  2. Assuming anti-HBcore-positive patients don't need prophylaxis - Rituximab is high-risk; strongly consider prophylaxis even with negative HBV-DNA 2

  3. Delaying vaccination until "later" - Once rituximab is started, vaccine efficacy plummets for 6-12 months. Vaccinate first, then start rituximab 2+ weeks later 7, 8

  4. Giving live vaccines - Absolutely contraindicated with rituximab

  5. Inadequate monitoring intervals - HBV-DNA and liver enzymes should be checked every 3-6 months in at-risk patients not on prophylaxis 2

References

Related Questions

Which hepatitis B tests should be performed before initiating rituximab therapy?
What vaccinations should be administered before starting rituximab therapy?
Is hepatitis B screening (HBsAg and anti‑HBc) required before initiating baricitinib therapy?
What precautions should be taken before and during rituximab therapy?
What are the indications, recommended biologic agents, dosing regimens, baseline screening requirements, and monitoring guidelines for patients with moderate-to-severe inflammatory or autoimmune diseases who have not achieved adequate control with conventional non‑biologic therapies?
Is sacubitril‑valsartan recommended for patients with heart failure with preserved ejection fraction?
What is the appropriate management for a 66‑year‑old woman with diabetes, ischemic heart disease, recent coronary artery stent placement, active upper‑gastrointestinal bleeding, gait ataxia, normocytic anemia, leukocytosis, chronic lacunar infarct, a left renal complex mass, persistent hypokalemia, and impaired renal function (serum creatinine 1.7 mg/dL)?
Can rotavirus vaccine products be interchanged for a child?
What is the specific laboratory marker for autoimmune pulmonary alveolar proteinosis?
How is asthma diagnosed in an adult patient?
In a patient currently taking sertraline 200 mg daily, olanzapine 10 mg daily, clonazepam 0.5 mg nightly, and valproate 500 mg daily, can cariprazine be initiated for negative symptoms of schizophrenia, and what is the appropriate starting dose and titration schedule?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.